Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to
increased morbidity and mortality, which must be reduced by both preventive measures and …

Background Malaria in pregnancy is associated with maternal and fetal morbidity and
mortality. In 2006, WHO recommended use of artemisinin-based combination treatments …

Background To date no comparative trials have been done, to our knowledge, of fixed-dose
artemisinin combination therapies (ACTs) for the treatment of Plasmodium falciparum …

Artemether-lumefantrine antimalarial efficacy in pregnancy could be compromised by
reduced drug exposure. Population-based simulations suggested that therapeutic efficacy …

Background Safety data regarding exposure to artemisinin-based combination therapy in
pregnancy are limited. This prospective cohort study conducted in Zambia evaluated the …

Abstract Background The World Health Organization presently recommends Artemisinin-
based combination therapy (ACT) as first-line therapy for uncomplicated P. falciparum …

Background Malaria in pregnancy affects both the mother and the fetus. However, evidence
supporting treatment guidelines for uncomplicated (including asymptomatic) falciparum …

Background There is limited data available regarding safety profile of artemisinins in early
pregnancy. They are, therefore, not recommended by WHO as a first-line treatment for …

Background In general, safety data following exposure to drugs in the first trimester of
pregnancy are scarce. More specifically, data on the safety of artemisinin-based …

Background: Information regarding the safety and efficacy of artemisinin combination
treatments for malaria in pregnant women is limited, particularly among women who live in …